Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Vaccinations

Vaccinations

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A two-step centrifugal microfluidic platform for semi-automated IGRA detection of tuberculosis based on chemiluminescence.

The Analyst·2026

Same author

Broad Neutralizing Antibodies Against SARS-CoV-2: Current Progress and Engineering Strategies.

Viruses·2026

Same author

Molecular basis of host ATP level modulation by actin-dependent secreted bacterial ATPase and its metaeffector.

Nature communications·2026

Same author

Structural basis and immunogenic efficacy of porcine circovirus type 3 virus-like particle.

Nature communications·2026

Same author

Sexual dimorphism of COVID-19 inspires drug repositioning and host-targeting immunotherapy for viral pneumonia.

Signal transduction and targeted therapy·2026

Same author

An All-in-One Microfluidic Platform for POCT-Ready Nucleic Acid Extraction from Heterogeneous Clinical Samples.

Analytical chemistry·2026

Search research articles

Related Experiment Video

Updated: Sep 13, 2025

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

Research Progress on Varicella-Zoster Virus Vaccines.

Hongjing Liu^1,2, Lingyan Cui^1,2, Sibo Zhang^1,2

¹State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, School of Life Sciences, Xiamen University, Xiamen 361102, China.

|July 30, 2025

Summary

Varicella-zoster virus (VZV) vaccines significantly reduce chickenpox and shingles. New vaccine technologies promise improved safety and immunity for public health.

Keywords:

cell-mediated immunity herpes zoster vaccine platforms vaccines varicella varicella-zoster virus

More Related Videos

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

Published on: October 30, 2016

Rapid, Seamless Generation of Recombinant Poxviruses using Host Range and Visual Selection

Rapid, Seamless Generation of Recombinant Poxviruses using Host Range and Visual Selection

Published on: May 24, 2020

Related Experiment Videos

Last Updated: Sep 13, 2025

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

Published on: October 30, 2016

Rapid, Seamless Generation of Recombinant Poxviruses using Host Range and Visual Selection

Rapid, Seamless Generation of Recombinant Poxviruses using Host Range and Visual Selection

Published on: May 24, 2020

Area of Science:

Virology
Immunology
Vaccinology

Background:

Varicella-zoster virus (VZV) causes chickenpox and shingles, posing public health risks due to high transmissibility and complications.
Current VZV vaccines, including live attenuated and recombinant subunit types, have reduced disease incidence but present safety and efficacy challenges.
Immunocompromised individuals and vaccine side effects remain key concerns for VZV prevention.

Purpose of the Study:

To review current Varicella-zoster virus (VZV) vaccine technologies and their impact on public health.
To analyze the mechanisms, clinical applications, and immunization strategies of existing and emerging VZV vaccines.
To explore future directions in VZV vaccine development for enhanced disease prevention.

Main Methods:

Literature review of VZV vaccine mechanisms, clinical data, and immunization strategies.
Synthesis of current knowledge on live attenuated, recombinant subunit, mRNA, viral vector, and VLP vaccines.
Analysis of vaccine safety, immunogenicity, and efficacy in diverse populations.

Main Results:

VZV vaccines have substantially decreased varicella and herpes zoster incidence globally.
Live attenuated vaccines raise safety concerns in immunocompromised populations.
Recombinant subunit vaccines show high efficacy but have side effects and adjuvant limitations.

Conclusions:

Advancements in vaccine technology, such as mRNA and VLP platforms, offer improved safety and durable immunity against VZV.
Continued research is crucial to optimize VZV vaccine strategies and maximize their public health impact.
VZV vaccines are essential tools for preventing severe VZV-related diseases.